On June 1, 2021 BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, reported that two abstracts have been accepted for online publication for the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting (Press release, BostonGene, JUN 1, 2021, View Source [SID1234583344]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to have multiple abstracts accepted for online publication," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our findings underscore the importance of the application of novel and cutting-edge analytical tools to understand the composition and activity of the tumor and the microenvironment, which will improve treatment outcomes for cancer patients."
The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings.
Details about the abstracts selected for publication can be found below:
Abstract Number: e15050
Title: The development of a computational machine learning tool to decipher malignant cell gene expression from complex tumor tissue
Complex tumor tissue is composed of malignant cells and diverse tumor microenvironment (TME) cellular populations. The percentage of malignant cells present in tumor tissue varies by cancer type, with percentages sometimes falling below 10%. TME cellular transcripts may comprise the majority of the total transcripts in a tumor, potentially resulting in biases during biomarker development and for clinical decision-making. A computational tool was created to "subtract" TME-specific gene expression from total gene expression in an array of solid tumors, producing in silico "purified” malignant cell gene expression.
Abstract Number: e15085
Title: Analytical and clinical validation of the BostonGene Tumor Portrait assay
Analysis of the genetic and transcriptomic profile of solid tumors using next-generation sequencing (NGS) assays is fundamental to propel precision medicine into clinical practice. NGS technology applied to tumor analysis allows for the characterization of somatic alterations, clonality, altered gene expression, and other parameters using a small amount of tissue. The BostonGene Tumor Portrait TestsTM, which integrate whole-exome sequencing (WES) and mRNA sequencing (RNA-seq), were developed to uncover cancer-promoting and -suppressing activity of the tumor and the tumor microenvironment (TME).